NDASUBCUTANEOUSSOLUTION
Approved
Oct 2024
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
2/8 — Basic
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VYALEV (foscarbidopa/foslevodopa) is a subcutaneous solution for Parkinson's disease, representing a prodrug formulation of levodopa and carbidopa designed for continuous subcutaneous infusion. The mechanism leverages dopamine replacement therapy via the foscarnet prodrug delivery system to maintain steady-state dopaminergic levels and reduce motor fluctuations.
Growth14.1 years to LOE
Recently approved product in growth phase with zero competitive pressure, suggesting expanding team headcount and high commercial investment intensity.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
VYALEV represents a high-visibility launch opportunity in a specialized neurology segment with zero competitive interference and 14+ years of patent protection. Career roles will focus on establishing market awareness, building specialist relationships, and capturing share from existing infusion modalities in advanced Parkinson's disease.
Brand ManagerRegional Sales Manager
Worked on VYALEV at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.